Philip Newland-Jones: key facts
- Kind of voice
- Clinician
- Role
- Consultant Pharmacist in Diabetes and Endocrinology and Honorary Associate Professor at the University of Southampton
- Quoted on
- Diabetes
- Tracked press citations
- 4
- Most recently quoted
- 30 Sept 2026
“At Southampton Medical School, our students are taught by pharmacologists, dieticians, pharmacists, nurses and doctors, precisely because each of those areas has a unique specialty within diabetes care.”
What Philip Newland-Jones has said
“it brought NICE recommendations in line with other international guidelines with "a less glucose-centric approach, focusing on cardiovascular risk and obesity along with prevention of small vessel complications linked with glucose exposure"”
consultant pharmacist in diabetes and endocrinology at the University of Southampton · Diabetes · 30 Sept 2026 · NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidance ↗
“Of course, teplizumab is significant because this is the first disease-modifying therapy for type 1 diabetes but you have to remember that this is a medicine that doesn't currently have a screening pathway.”
consultant pharmacist and honorary associate professor in diabetes and endocrinology at the University of Southampton · Diabetes · 29 Sept 2026 · Can immunotherapy stop the clock on type 1 diabetes? ↗
“The introduction, initiation and titration of once-weekly insulin represents a significant change in diabetes care for specialists and other insulin prescribers. National guidance, alongside practical multidisciplinary consensus recommendations, will be needed to support the safe, effective and consistent use of these therapies across clinical settings.”
consultant pharmacist in diabetes and endocrinology at the University of Southampton · Diabetes · 27 Aug 2026 · Once-weekly insulin would be ‘significant change’ for diabetes prescribers ↗
Where Philip Newland-Jones has been quoted
- “It takes a village”: the importance of multidisciplinary teams in diabetes caresouthampton.ac.uk · 30 Sept 2026
- NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidancepharmaceutical-journal.com · 30 Sept 2026
- Can immunotherapy stop the clock on type 1 diabetes?pharmaceutical-journal.com · 29 Sept 2026
- Once-weekly insulin would be ‘significant change’ for diabetes prescriberspharmaceutical-journal.com · 27 Aug 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.